Company: BGLC
Filing Date: 2025-11-14
Form Type: PRE 14A
Source: 0001477932-25-008317
Chunk: 32

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: PRE 14A
Chunk 32
---
. Wei Li Leong tendered her resignation letter to the Company on October 30, 2023.                                                                  |
| (6) | Mr. Liong Tai Tan tendered his resignation to the Company on August 31, 2023.                                                                         |
| (7) | Mr. Tan Lee began his position on September 1, 2023.                                                                                                  |

| 23 |

<div align='center'>Employment Agreements

Employment Agreement between Mr. Su-Leng Tan Lee and BioNexus</div>

Effective as of August 15, 2023, BioNexus entered into an employment agreement with Mr. Su-Leng Tan Lee. The agreement provides for an annual base salary. Mr. Tan Lee’s employment will terminate two years from the effective date of the agreement, and such term shall be automatically extended for a one-year term thereafter at the Company’s request. The agreement further provides that either party to the agreement may terminate Mr. Tan Lee’s employment upon one month’s prior written notice. Additionally, the agreement provides that Mr. Tan Lee shall not, during the term of the agreement and for 24 months after cessation of employment, carry on business in competition with the Company.

<div align='center'>Grants of Plan-Based Awards</div>

Except as stated above, no plan-based awards were granted to any of our named executive officers during the interim fiscal year ended December 31, 2024.

<div align='center'>Outstanding Equity Awards at Interim Fiscal Year End</div>

The equity awards reflected in the Summary Compensation Table above represents all restricted stock awards issued to our executive officers as of December 31, 2024. No other stock or stock option awards were granted to any other officer of the Company as of December 31, 2024.

<div align='center'>Option Exercises and Stock Vested</div>

No option to purchase our capital stock was exercised by any of our named executive officers, nor was any restricted stock held by such executive officers vested during the interim fiscal period ended December 31, 2024.

<div align='center'>Pension Benefits</div>

No named executive officers received or held pension benefits during the interim fiscal period ended December 31, 2024.

| 24 |

<div align='center'>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</div>

The following table sets forth certain information known to us as of November [*], 2025 except where another date is noted below), with respect